144 related articles for article (PubMed ID: 38604268)
1. A role for RIO kinases in the crosshair of cancer research and therapy.
Ghandadi M; Dobi A; Malhotra SV
Biochim Biophys Acta Rev Cancer; 2024 May; 1879(3):189100. PubMed ID: 38604268
[TBL] [Abstract][Full Text] [Related]
2. The atypical protein kinase RIOK3 contributes to glioma cell proliferation/survival, migration/invasion and the AKT/mTOR signaling pathway.
Zhang T; Ji D; Wang P; Liang D; Jin L; Shi H; Liu X; Meng Q; Yu R; Gao S
Cancer Lett; 2018 Feb; 415():151-163. PubMed ID: 29233656
[TBL] [Abstract][Full Text] [Related]
3. A kinome-wide RNAi screen in Drosophila Glia reveals that the RIO kinases mediate cell proliferation and survival through TORC2-Akt signaling in glioblastoma.
Read RD; Fenton TR; Gomez GG; Wykosky J; Vandenberg SR; Babic I; Iwanami A; Yang H; Cavenee WK; Mischel PS; Furnari FB; Thomas JB
PLoS Genet; 2013; 9(2):e1003253. PubMed ID: 23459592
[TBL] [Abstract][Full Text] [Related]
4. The Atypical Kinase RIOK1 Promotes Tumor Growth and Invasive Behavior.
Weinberg F; Reischmann N; Fauth L; Taromi S; Mastroianni J; Köhler M; Halbach S; Becker AC; Deng N; Schmitz T; Uhl FM; Herbener N; Riedel B; Beier F; Swarbrick A; Lassmann S; Dengjel J; Zeiser R; Brummer T
EBioMedicine; 2017 Jun; 20():79-97. PubMed ID: 28499923
[TBL] [Abstract][Full Text] [Related]
5. Aurora-A kinase regulates NF-kappaB activity: lessons from combination studies.
Linardopoulos S
J BUON; 2007 Sep; 12 Suppl 1():S67-70. PubMed ID: 17935280
[TBL] [Abstract][Full Text] [Related]
6. Aurora kinases: new targets for cancer therapy.
Carvajal RD; Tse A; Schwartz GK
Clin Cancer Res; 2006 Dec; 12(23):6869-75. PubMed ID: 17145803
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of human RIOK2 bound to a specific inhibitor.
Wang J; Varin T; Vieth M; Elkins JM
Open Biol; 2019 Apr; 9(4):190037. PubMed ID: 30991936
[TBL] [Abstract][Full Text] [Related]
8. Targeting oncogenic Raf protein-serine/threonine kinases in human cancers.
Roskoski R
Pharmacol Res; 2018 Sep; 135():239-258. PubMed ID: 30118796
[TBL] [Abstract][Full Text] [Related]
9. New paradigms in anticancer therapy: targeting multiple signaling pathways with kinase inhibitors.
Faivre S; Djelloul S; Raymond E
Semin Oncol; 2006 Aug; 33(4):407-20. PubMed ID: 16890796
[TBL] [Abstract][Full Text] [Related]
10. Aurora kinase inhibitors as anticancer molecules.
Katayama H; Sen S
Biochim Biophys Acta; 2010; 1799(10-12):829-39. PubMed ID: 20863917
[TBL] [Abstract][Full Text] [Related]
11. Aurora kinase inhibitors as anti-cancer therapy.
Lok W; Klein RQ; Saif MW
Anticancer Drugs; 2010 Apr; 21(4):339-50. PubMed ID: 20016367
[TBL] [Abstract][Full Text] [Related]
12. A review on the role of TANK-binding kinase 1 signaling in cancer.
Alam M; Hasan GM; Hassan MI
Int J Biol Macromol; 2021 Jul; 183():2364-2375. PubMed ID: 34111484
[TBL] [Abstract][Full Text] [Related]
13. Aurora-B kinase inhibitors for cancer chemotherapy.
Yeung SC; Gully C; Lee MH
Mini Rev Med Chem; 2008 Dec; 8(14):1514-25. PubMed ID: 19075809
[TBL] [Abstract][Full Text] [Related]
14. AURKA inhibitors: right in time.
Kovar H
Pediatr Blood Cancer; 2010 Jul; 55(1):3-4. PubMed ID: 20486161
[No Abstract] [Full Text] [Related]
15. PIM1 kinase as a target for cancer therapy.
Merkel AL; Meggers E; Ocker M
Expert Opin Investig Drugs; 2012 Apr; 21(4):425-36. PubMed ID: 22385334
[TBL] [Abstract][Full Text] [Related]
16. New inhibitors of the mammalian target of rapamycin signaling pathway for cancer.
Albert S; Serova M; Dreyer C; Sablin MP; Faivre S; Raymond E
Expert Opin Investig Drugs; 2010 Aug; 19(8):919-30. PubMed ID: 20569080
[TBL] [Abstract][Full Text] [Related]
17. Tribbles-Related Protein Family Members as Regulators or Substrates of the Ubiquitin-Proteasome System in Cancer Development.
Sakai S; Miyajima C; Uchida C; Itoh Y; Hayashi H; Inoue Y
Curr Cancer Drug Targets; 2016; 16(2):147-56. PubMed ID: 26560117
[TBL] [Abstract][Full Text] [Related]
18. Molecular targets for cancer therapy in the PI3K/AKT/mTOR pathway.
Polivka J; Janku F
Pharmacol Ther; 2014 May; 142(2):164-75. PubMed ID: 24333502
[TBL] [Abstract][Full Text] [Related]
19. Breaking the DNA Damage Response via Serine/Threonine Kinase Inhibitors to Improve Cancer Treatment.
Rozpędek W; Pytel D; Nowak-Zduńczyk A; Lewko D; Wojtczak R; Diehl JA; Majsterek I
Curr Med Chem; 2019; 26(8):1425-1445. PubMed ID: 29345572
[TBL] [Abstract][Full Text] [Related]
20. Potent and selective inhibitors of Akt kinases slow the progress of tumors in vivo.
Luo Y; Shoemaker AR; Liu X; Woods KW; Thomas SA; de Jong R; Han EK; Li T; Stoll VS; Powlas JA; Oleksijew A; Mitten MJ; Shi Y; Guan R; McGonigal TP; Klinghofer V; Johnson EF; Leverson JD; Bouska JJ; Mamo M; Smith RA; Gramling-Evans EE; Zinker BA; Mika AK; Nguyen PT; Oltersdorf T; Rosenberg SH; Li Q; Giranda VL
Mol Cancer Ther; 2005 Jun; 4(6):977-86. PubMed ID: 15956255
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
